Trial Profile
A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Feb 2014 Results published in the Drugs and Aging.
- 24 May 2010 Actual end date (April 2006) added as reported by ClinicalTrials.gov.